A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 45, Issue 4, 2015, Pages 1157-1173

  Olazarán, Javier ^a   Gil De Gómez, Luis ^b   Rodríguez Martín, Andrés ^b   Valentí Soler, Meritxell ^a   Frades Payo, Belén ^a   Marín Muñoz, Juan ^c   Antúnez, Carmen ^c   Frank García, Ana ^d   Acedo Jiménez, Carmen ^d   Morlán Gracia, Lorenzo ^e   Petidier Torregrossa, Roberto ^e   Guisasola, María Concepción ^f   Bermejo Pareja, Félix ^g,h,i   Sánchez Ferro, Álvaro ^j   Pérez Martínez, David A ^k   Manzano Palomo, Sagrario ^k   Farquhar, Ruth ^l   Rábano, Alberto ^a   Calero, Miguel ^m  

^a Instituto de Salud Carlos III   (Spain)

^b BIOCROSS SL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

ⁱ UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^j MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^k HOSPITAL INFANTA CRISTINA   (Spain)

^l EXPLORISTICS LTD   (United Kingdom)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

more..

Author keywords

Alzheimer's disease; biomarkers; diagnosis; mild cognitive impairment; plasma

Indexed keywords

ACID; ACYLCARNITINE; ALANINE; ASPARTIC ACID; BIOLOGICAL MARKER; CHOLESTEROL ESTER; DEOXYCHOLIC ACID; DOCOSAHEXAENOIC ACID; GLUTAMIC ACID; GLYCEROLIPID; GLYCEROPHOSPHOLIPID; PHOSPHATIDYLETHANOLAMINE; SPHINGOLIPID; SPHINGOMYELIN; STEROID; APOLIPOPROTEIN E;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; COGNITION; COMORBIDITY; COMPARATIVE STUDY; CONFOUNDING VARIABLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL EXAMINATION; MENTAL HEALTH; METABOLITE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROLOGIC EXAMINATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ALGORITHM; AREA UNDER THE CURVE; BLOOD; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ALZHEIMER DISEASE; APOLIPOPROTEINS E; AREA UNDER CURVE; BIOMARKERS; CROSS-SECTIONAL STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MASS SPECTROMETRY; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 84928152102     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142925     Document Type: Article

References (62)

1. Alzheimer's Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Prince MJ, Acosta D, Castro-Costa E, Jackson J, Shaji KS (2009) Packages of care for dementia in low-and middleincome countries. PLoS Med 6, e1000176.
3. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA (2004) Molecular pathways to neurodegeneration. Nat Med 10(Supp l), S2-S9.
4. Selkoe DJ (2003) Folding proteins in fatal ways. Nature 426, 900-904.
5. Holtzman DM (2011) CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging 32(Suppl 1), S4-S9.
6. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
7. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH (2011) The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 270-279.
8. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B (2001) Current concepts in mild cognitive impairment. Arch Neurol 58, 1985-1992.
9. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, Marcus D, Morris JC, Holtzman DM (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease.EMBO Mol Med 1, 371-380.
10. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ (2009) Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 65, 403-413.
11. Frank RA, GalaskoD, Hampel H, Hardy J, de Leon MJ,Mehta PD, Rogers J, Siemers E, Trojanowski JQ (2003) Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol Aging 24, 521-536.
12. Schneider P, Hampel H, Buerger K (2009) Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. CNS Neurosci Ther 15, 358-374.
13. Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN, Alzheimer's Disease Neuroimaging I, Australian Imaging B, Lifestyle Research G (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 69, 1318-1325.
14. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R, Texas Alzheimer's R, Care C, Alzheimer's Disease Neuroimaging I (2011) A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS One 6, e28092.
15. Hu WT, Holtzman DM, Fagan AM, Shaw LM, Perrin R, Arnold SE, Grossman M, Xiong C, Craig-Schapiro R, Clark CM, Pickering E, Kuhn M, Chen Y, Van Deerlin VM, McCluskey L, Elman L, Karlawish J, Chen-Plotkin A, Hurtig HI, Siderowf A, Swenson F, Lee VM, Morris JC, Trojanowski JQ, Soares H (2012) Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology 79, 897-905.
16. Llano DA, Laforet G, Devanarayan V (2011) Derivation of a newADAS-cog composite using tree-based multivariate analysis: Prediction of conversion from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord 25, 73-84.
17. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, Friedman LF, Galasko DR, Jutel M, Karydas A, Kaye JA, Leszek J, Miller BL, Minthon L, Quinn JF, Rabinovici GD, Robinson WH, Sabbagh MN, So YT, Sparks DL, Tabaton M, Tinklenberg J, Yesavage JA, Tibshirani R, Wyss-Coray T (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13, 1359-1362.
18. Hye A, Riddoch-Contreras J, Baird AL, Ashton NJ, Bazenet C, Leung R, Westman E, Simmons A, Dobson R, Sattlecker M, Lupton M, Lunnon K, Keohane A,Ward M, Pike I, Zucht HD, Pepin D, ZhengW, Tunnicliffe A, Richardson J, Gauthier S, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S (2014) Plasma proteins predict conversion to dementia from prodromal disease. Alzheimers Dement 10, 799-807.e2.
19. Mapstone M, Cheema AK, Fiandaca MS, Zhong X, Mhyre TR, MacArthur LH, Hall WJ, Fisher SG, Peterson DR, Haley JM, Nazar MD, Rich SA, Berlau DJ, Peltz CB, Tan MT, Kawas CH, Federoff HJ (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418.
20. Wood PL (2012) Lipidomics of Alzheimer's disease: Current status. Alzheimers Res Ther 4, 5.
21. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R (2011) Metabolomics in early Alzheimer's disease: Identification of altered plasma sphingolipidome using shotgun lipidomics. PLos One 6, :e21643.
22. Whiley L, Sen A, Heaton J, Proitsi P, Garcia-Gomez D, Leung R, Smith N, Thambisetty M, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Lovestone S, Legido-Quigley C (2014) Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging 35, 271-278.
23. Thambisetty M, Lovestone S (2010) Blood-based biomarkers of Alzheimer's disease: Challenging but feasible. Biomark Med 4, 65-79.
24. GalaskoD, Golde TE (2013) Biomarkers for Alzheimer's disease in plasma, serum and blood-conceptual and practical problems. Alzheimers Res Ther 5, 10.
25. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
26. Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114, 797-811.
27. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L (1975) Cerebral blood flow in dementia. Arch Neurol 32, 632-637.
28. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572.
29. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56, 303-308.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
31. Calero O, Hortiguela R, Bullido MJ, Calero M (2009) Apolipoprotein E genotyping method by real time PCR, a fast and cost-effective alternative to the TaqMan and FRET assays. J Neurosci Methods 183, 238-240.
32. Baker M (2011) Metabolomics: From small molecules to big ideas. Nat Meth 8, 117-121.
33. Duportet X, Aggio R, Carneiro S, Villas-Bôas S (2012) The biological interpretation of metabolomic data can be misled by the extraction method used. Metabolomics 8, 410-421.
34. Grumbach E, Wheat T, Mazzeo J (2010) A novel method for the analysis of amino acids. Waters Application notes. 2007 Lib. Number WA43226.
35. van der Kloet FM, Bobeldijk I,Verheij ER, JellemaRH(2009) Analytical error reduction using single point calibration for accurate and precise metabolomic phenotyping. J Proteome Res 8, 5132-5141.
36. Butterfield DA, Pocernich CB (2003) The glutamatergic system and Alzheimer's disease: Therapeutic implications. CNS Drugs 17, 641-652.
37. Ilzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M (2003) Plasma amino acids percentages in amyotrophic lateral sclerosis patients. Neurol Sci 24, 293-295.
38. Basun H, Forssell LG, Almkvist O, Cowburn RF, Eklof R, Winblad B, Wetterberg L (1990) Amino acid concentrations in cerebrospinal fluid and plasma in Alzheimer's disease and healthy control subjects. J Neural Transm Park Dis Dement Sect 2, 295-304.
39. D'Aniello A, Fisher G, Migliaccio N, Cammisa G, D'Aniello E, Spinelli P (2005) Amino acids and transaminases activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Lett 388, 49-53.
40. Malinow R (2012) New developments on the role of NMDA receptors in Alzheimer's disease. Curr Opin Neurobiol 22, 559-563.
41. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003) Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348, 1333-1341.
42. Tsai PJ, Huang PC (1999) Circadian variations in plasma and erythrocyte concentrations of glutamate, glutamine, and alanine in men on a diet without and with added monosodium glutamate. Metabolism 48, 1455-1460.
43. Haughey NJ, Bandaru VV, Bae M, Mattson MP (2010) Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim Biophys Acta 1801, 878-886.
44. Mielke MM, Lyketsos CG (2010) Alterations of the sphingolipid pathway in Alzheimer's disease: New biomarkers and treatment targets? Neuromolecular Med 12, 331-340.
45. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC (2010) Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 31, 17-24.
46. Mielke MM, Ratnam Bandaru VV, Haughey NJ, Xia J, P, Yasar FL, Varma S, Harris V, Schneider G, Rabins EB, Bandeen-Roche PV, Lyketsos K, Carlson CG, MC (2012) Serum ceramides increase the risk of Alzheimer disease. Neurology 79, 633-641.
47. Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, Mori S, Miller MI, Ceritoglu C, Brown T, Albert M, Lyketsos CG (2010) Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement 6, 378-385.
48. Cunnane SC, Schneider JA, Tangney C, Tremblay-Mercier J, Fortier M, Bennett DA, Morris MC (2012) Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis 29, 691-697.
49. Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, Robins SJ, Au R, Tucker KL, Kyle DJ, Wilson PW, Wolf PA (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch Neurol 63, 1545-1550.
50. Walter A,Korth U, Hilgert M, Hartmann J,Weichel O, Hilgert M, Fassbender K, Schmitt A, Klein J (2004) Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 25, 1299-1303.
51. Bennett SA, Valenzuela N, Xu H, Franko B, Fai S, Figeys D (2013) Using neurolipidomics to identify phospholipid mediators of synaptic (dys)function in Alzheimer's Disease. Front Physiol 4, 168.
52. Han X, Holtzman DM, McKeel DW Jr (2001) Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: Molecular characterization using electrospray ionization mass spectrometry. J Neurochem 77, 1168-1180.
53. Yurko-Mauro K (2010) Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res 7, 190-196.
54. Astarita G, Jung KM, Berchtold NC, Nguyen VQ, Gillen DL, Head E, Cotman CW, Piomelli D (2010) Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 5, e12538.
55. Young EA, Abelson J, Lightman SL (2004) Cortisol pulsatility and its role in stress regulation and health. Front Neuroendocrinol 25, 69-76.
56. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P (2009) Bile acids as regulatory molecules. J Lipid Res 50, 1509-1520.
57. Ogundare M, Theofilopoulos S, Lockhart A, Hall LJ, Arenas E, Sjovall J, Brenton AG,Wang Y, Griffiths WJ (2010) Cerebrospinal fluid steroidomics: Are bioactive bile acids present in brain? J Biol Chem 285, 4666-4679.
58. Sattlecker M, Kiddle SJ, Newhouse S, Proitsi P, Nelson S, Williams S, Johnston C, Killick R, Simmons A, Westman E, Hodges A, Soininen H, Kloszewska I, Mecocci P, Tsolaki M, Vellas B, Lovestone S, the AddNeuroMed C, Dobson RJ (2014) Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimers Dement 10, 724-734.
59. Roe CM, Fagan AM,Williams MM, Ghoshal N, Aeschleman M, Grant EA, Marcus DS, MintunMA,HoltzmanDM,Morris JC (2011) Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease. Neurology 76, 501-510.
60. FaganAM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
61. Bjorkqvist M, Ohlsson M, Minthon L, Hansson O (2012) Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. PLoS One 7, e29868.
62. Ioannidis JP, Panagiotou OA (2011) Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 305, 2200-2210.